CHC is among the least common primary liver malignancies, accounting for a small fraction of hepatic cancers but punching well above its weight in clinical severity. Unlike classic hepatocellular carcinoma or cholangiocarcinoma, CHC exhibits features of both tumor types, and clinicians have long observed that it can seed distant metastases even at early stages. Because the disease is rare, large-scale studies of its metastatic behavior have been scarce, and no standardized tool has existed to help oncologists gauge which patients are most likely to develop distant spread. The new study set out to fill that gap by combining a large international registry with modern machine learning algorithms.

The researchers drew on data from the Surveillance, Epidemiology, and End Results (SEER) database, assembling a cohort of 1,180 patients diagnosed with CHC between 2000 and 2020. This population was randomly split into a training set and an internal test set in a 7:3 ratio, a standard practice that allows models to learn patterns from one portion of data while being evaluated on unseen cases. To guard against the possibility that the model had merely memorized quirks of the American registry, the team also assembled an external validation set of 125 CHC patients diagnosed at their own hospital between 2011 and 2018. Patients were categorized into a metastasis group and a non-metastasis group according to whether distant metastasis had occurred.

The analytical pipeline proceeded in several carefully staged steps. First, univariate and multivariate logistic regression analyses were applied to the training data to identify candidate risk factors influencing distant metastasis. Feature selection was then refined using random forest importance measures combined with forward feature importance sequencing, a technique that progressively adds variables in order of their contribution to predictive performance. Six variables ultimately survived this screening process and formed the basis of the final decision model. These features were then fed into six different machine learning algorithms, each trained to distinguish metastatic from non-metastatic cases, with 10-fold cross-validation employed to ensure that performance estimates were stable rather than artifacts of a single data partition.

Model evaluation relied on an ensemble of complementary metrics rather than any single figure of merit. Receiver operating characteristic (ROC) curves quantified the trade-off between sensitivity and specificity across decision thresholds; precision-recall curves (PRC) assessed performance under class imbalance, a common challenge in metastasis prediction where metastatic cases are the minority; calibration curves evaluated whether predicted probabilities matched observed outcomes; and confusion matrices provided a direct accounting of correct and incorrect classifications. Among the six algorithms tested, extreme gradient boosting, commonly abbreviated as XGBoost or XGB, emerged as the clear frontrunner.

On the internal test set, the XGB model achieved a ROC area under the curve of 0.863, an accuracy of 0.802, a sensitivity of 0.875, and a precision-recall area under the curve of 0.642. The sensitivity figure is particularly notable in an oncology context: it means the model correctly identified approximately 87.5 percent of patients who did develop distant metastasis, minimizing the dangerously false-negative errors that could lead to undertreatment. The 10-fold cross-validation results were even more striking, yielding a ROC AUC of 0.989 with a standard error of just 0.019, suggesting that the model’s internal performance is both high and consistent across different data subsets. In external validation and case-based analysis, the model continued to demonstrate utility, with the authors reporting that two typical case studies confirmed its reliability in individual patient scenarios.

One of the study’s most important contributions lies in its treatment of interpretability. Machine learning models in medicine are frequently criticized as “black boxes” — systems whose predictions cannot be easily traced to underlying reasoning, a serious obstacle to clinical adoption. To address this, the researchers applied Shapley additive explanations, or SHAP, a technique borrowed from cooperative game theory that assigns each input variable a quantified contribution to every individual prediction. The SHAP analysis revealed a clear hierarchy of risk drivers for distant metastasis in CHC: lymph node status, surgical treatment, age, tumor grade, primary site, and race emerged as the top six influential variables. By showing how each factor pushes an individual patient’s predicted risk up or down, SHAP transforms the model from an opaque score generator into a transparent decision aid that clinicians can interrogate.

The identified risk factors themselves carry clinical meaning. Lymph node involvement, a well-established marker of tumor aggressiveness and spread, topped the ranking, while the absence of surgery — often a proxy for advanced or inoperable disease — ranked second. Age and tumor grade align with general oncological expectations that older patients and poorly differentiated tumors fare worse. The appearance of primary site and race among the leading variables hints at both anatomical and potentially demographic or access-related influences on metastatic behavior, raising questions the authors suggest warrant further investigation in prospective cohorts.

To translate the research into practice, the team built a web-based risk calculator anchored on the XGB model, allowing clinicians to input patient characteristics and receive an individualized metastasis risk estimate. Such tools occupy a growing niche in oncology, where treatment intensity — from surgical resection to systemic therapy and surveillance frequency — increasingly depends on precise risk stratification. For CHC in particular, where distant metastasis can drastically shorten survival and treatment windows are narrow, a validated pre-treatment risk estimate could meaningfully inform decisions about staging workups, therapeutic aggressiveness, and patient counseling.

The study’s limitations are those inherent to its design. As a retrospective cohort study relying largely on registry data, it inherits the constraints of SEER coding, including potential under-capture of detailed molecular and imaging information that a prospective study might record. The external validation cohort, while valuable, comprises 125 patients from a single Chinese institution, and broader multi-institutional prospective validation will be needed before the tool can be recommended for universal clinical deployment. Nevertheless, the combination of robust internal metrics, external validation, explainable AI methodology, and an immediately deployable web calculator marks this work as a substantive step toward data-driven management of one of the liver’s most challenging cancers. The authors conclude that their XGBoost-based system outperforms alternative machine learning approaches in recognizing distant metastasis in CHC and possesses a high degree of utility and reliability for informing clinical treatment decisions.

Distant metastasis is the most consequential stage of breast cancer progression because tumor cells that travel to organs such as the bone, liver, lungs, or brain are responsible for most breast cancer-related deaths. Clinicians already use tumor stage, hormone-receptor status, HER2 expression, genomic tests, and other clinical factors to estimate risk, but these measures do not fully explain why patients with seemingly similar disease can follow very different trajectories. The new analysis adds to growing evidence that cancer prognosis may depend on molecular relationships operating within tumor cells, not simply on the level of one isolated gene.

The researchers focused on SUCLA2 and USP10 because both have biological links to cancer-related processes, although they operate in different molecular contexts. SUCLA2 encodes the beta subunit of succinyl-CoA ligase, an enzyme involved in mitochondrial energy metabolism and the tricarboxylic acid cycle. Mitochondria do more than generate energy: they also influence redox balance, biosynthesis, cell death, and the ability of cancer cells to adapt to stressful environments. USP10 encodes ubiquitin-specific peptidase 10, a deubiquitinating enzyme that removes ubiquitin tags from proteins. By regulating protein stability and signaling, deubiquitinating enzymes can affect pathways involved in DNA damage responses, cell survival, growth, and immune regulation.

Rather than examining the genes independently, the study assessed their combined expression patterns in four independent breast cancer cohorts containing information on distant metastasis-free survival. Patients were grouped according to the relationship between SUCLA2 and USP10 expression, allowing the researchers to test whether a molecular combination could distinguish risk more effectively than either biomarker alone. Survival differences were evaluated using Kaplan–Meier analyses, with patients divided according to an optimal cutoff determined through receiver operating characteristic, or ROC, analysis. Statistical significance was assessed with the log-rank test.

The strongest signal emerged in patients who had low SUCLA2 expression together with high USP10 expression. Among patients who had not received treatment, this molecular pattern was associated with significantly poorer DMFS, indicating a greater likelihood of developing distant metastases during follow-up. The result was notable because the risk pattern was not reproduced consistently when SUCLA2 or USP10 was considered separately. In other words, the prognostic information appeared to reside in the relationship between the genes rather than in the absolute expression of either one.

Treatment status substantially changed the association. In patients who received treatment, the elevated metastatic risk linked to low SUCLA2 and high USP10 was no longer observed. This finding does not establish that therapy directly neutralizes the biological effects of the gene interaction, because the analysis was observational and treatment decisions may have been influenced by clinical features that were not fully captured. However, it raises the possibility that treatment modifies the relationship between tumor metabolism, protein regulation, and metastatic behavior. It also suggests that a biomarker can perform differently in treated and untreated populations, an issue that is critical when developing clinically useful prediction tools.

The researchers further examined the product of SUCLA2 and USP10 expression, a mathematical representation of their combined activity. Kaplan–Meier curves for this interaction measure supported the idea that the joint signal could separate patients with different metastatic outcomes. Such interaction-based models are designed to capture situations in which the effect of one molecular factor depends on the level of another. This is biologically plausible in cancer, where metabolic pathways, protein turnover, stress responses, and treatment resistance are tightly interconnected. A gene that appears weakly informative on its own may become clinically meaningful when interpreted in the context of another pathway.

“Our results indicate that molecular interactions may provide more informative biomarkers than single-gene measurements,” the researchers noted. The conclusion reflects a broader shift in precision oncology. Many current approaches focus on identifying mutations or expression changes in individual genes, but tumors function as dynamic networks. A metabolic enzyme and a deubiquitinating enzyme may influence overlapping cellular systems without being part of a simple linear pathway. Their combined expression could therefore act as a proxy for a tumor state characterized by altered energy use, protein stability, stress tolerance, or metastatic capacity.

The findings could eventually help identify breast cancer patients who require closer surveillance or more intensive treatment, but substantial validation is still needed. The study relied on retrospective gene-expression and clinical datasets, and the cohorts may differ in tumor subtypes, treatment regimens, follow-up duration, and methods of molecular measurement. Laboratory experiments will be necessary to determine whether SUCLA2 and USP10 directly regulate one another or instead reflect a third biological process. Prospective clinical studies must also test whether the interaction remains predictive when adjusted for tumor stage, age, receptor status, chemotherapy, endocrine therapy, HER2-targeted treatment, and other established factors. If these results are confirmed, the SUCLA2–USP10 relationship could become both a prognostic tool and a starting point for investigating new strategies to limit metastatic progression.

Subject of Research: Not applicable

Article Title: SUCLA2-USP10 interaction rather than SUCLA2 alone correlates with metastasis in breast cancer patients

Web References: https://doi.org/10.70401/cbm.2026.0022

References: He X, Shao Y, Sun X. “SUCLA2-USP10 interaction rather than SUCLA2 alone correlates with metastasis in breast cancer patients.” Computational Biomedicine. DOI: 10.70401/cbm.2026.0022.

Image Credits: © He X, Shao Y, Sun X, 2026. Creative Commons Attribution 4.0 International License.

Keywords: breast cancer, distant metastasis-free survival, SUCLA2, USP10, gene interaction, biomarkers, precision oncology, tumor metabolism, deubiquitinating enzymes, Kaplan–Meier analysis